A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting that the development of C16-based lipopeptide...

Full description

Bibliographic Details
Main Authors: Qiaoshuai Lan, Jasper Fuk-Woo Chan, Wei Xu, Lijue Wang, Fanke Jiao, Guangxu Zhang, Jing Pu, Jie Zhou, Shuai Xia, Lu Lu, Kwok-Yung Yuen, Shibo Jiang, Qian Wang
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Viruses
Subjects:
palmitic acid
lipopeptide
Omicron
β-coronavirus
entry inhibitor
Online Access:https://www.mdpi.com/1999-4915/14/3/549

Internet

https://www.mdpi.com/1999-4915/14/3/549

Similar Items